Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September

11 Sep 2020

 

Oxurion to Host Conference Call following the H1 Financial Results         

Leuven, Belgium, 11 September 2020 – 08.15 A.M. CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies, with a focus on diabetic macular edema (DME), announces that the Company will issue its Business Update and First Half Financial Results on Thursday, September 17, 2020 at 5.45 p.m. CET.

Following the announcement, Oxurion’s management will host a conference call in English on Thursday, September 17 at 6.30 p.m. CET to discuss the Business Update, its Financial Results and to provide an overview of the progress and potential of the Company’s emerging DME Franchise.

Oxurion’s First Half 2020 Conference Call & Webcast Details:

Date: Thursday, September 17, 2020

Time: 6.30 p.m. CET / 5.30 p.m. BST

Participant telephone numbers:

Brussels: +32 (0) 2 789 8603

Belgium Toll Free: 0800 746 68

Standard International Access: +44 (0) 20 3003 2666

UK Toll Free: 0808 109 0700

USA Toll Free: 1 866 966 5335               

Password: Oxurion

There will be a live listen-only webcast of the event, accessible from the Oxurion website. 

Click here to register for the webcast

An on-demand version of the event will also be made available shortly after the event has finished.